Company profile
GlycoEra company profile
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases. It leverages its proprietary CustomGlycan platform to design biologics that selectively target and degrade disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. The company's lead program, GE8820, is engineered to degrade pathogenic IgG4 autoantibodies with high specificity and efficiency, addressing conditions like pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis. This approach offers the potential for earlier intervention and improved patient outcomes compared to existing therapies.
Business identity
- Website
- https://glycoera.com
- Contact email
- [email protected]
- Phone number
- +41 44 733 8575
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2020-01-01, Year
Headquarters
- Headquarters
- Schlieren, Zurich, Switzerland
- Postal code
- 8952
- Country code
- CH
- Continent
- Europe